Table 3.
Patients’ adherence according to treatment.
| Treatment | Value, n (%) | P value | ||||||||
|
|
Pre-App cohort (n=2966) | App nonused cohort (n=861) | App used cohort (n=648) |
|
||||||
| Chemotherapy | <.001 | |||||||||
|
|
Adherent | 2732 (92.1) | 808 (93.8) | 625 (96.5) |
|
|||||
|
|
Nonadherent | 234 (7.9) | 53 (6.2) | 23 (3.5) |
|
|||||
| Radiotherapy | .001 | |||||||||
|
|
Adherent | 2789 (94) | 809 (94) | 633 (97.7) |
|
|||||
|
|
Nonadherent | 177 (6) | 52 (6) | 15 (2.3) |
|
|||||
| Targeted therapya | .01 | |||||||||
|
|
Adherent | 594 (86.6) | 158 (91.9) | 170 (93.4) |
|
|||||
|
|
Nonadherent | 92 (13.4) | 14 (8.1) | 12 (6.6) |
|
|||||
| Endocrine therapyb | <.001 | |||||||||
|
|
Adherent | 2001 (91.2) | 637 (93.5) | 476 (96.4) |
|
|||||
|
|
Nonadherent | 194 (8.8) | 44 (6.5) | 18 (3.6) |
|
|||||
| Overall therapy | <.001 | |||||||||
|
|
Adherent | 2444 (82.4) | 747 (86.8) | 589 (90.9) |
|
|||||
|
|
Nonadherent | 522 (17.6) | 114 (13.2) | 59 (9.1) |
|
|||||
aIn 1028 patients with HER2-positive breast cancer.
bIn 3337 patients with hormone receptor–positive breast cancer.